Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus...
The FDA accepted CYTK’s new drug application (NDA) for lead pipeline candidate aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The regul